"Nutralliance shares Folium’s commitment to exceptional quality," said Folium Chief Executive Officer and Co-founder Kashif Shan . "That commitment coupled with their respected relationship-based approach to ingredient sales makes them the perfect partner to connect food & beverage, nutrition, animal nutrition and cosmeceutical product manufacturers with Folium’s phytocannabinoid-rich hemp oil raw materials and white-labeled products."
"The consumers our customers serve demand premium ingredients, and we’re committed to providing them with ingredient solutions that enable them to meet that growing need," said Brian Salerno , Nutralliance President and CEO. "Not all hemp is created equal, and Folium’s leadership in industrial hemp quality, safety and innovation is unmatched. That makes them a perfect addition to our expanding catalog of superior, science-based ingredients."
COLORADO SPRINGS, Colo. and YORBA LINDA, Calif. , Sept. 3, 2020 /PRNewswire/ — Hemp-derived non-psychoactive cannabinoid manufacturer Folium Biosciences and premium-ingredient sales and marketing company Nutralliance have entered a distribution partnership that grants Nutralliance the right to distribute Folium’s industry-leading 0.0% THC broad spectrum CBD oil products in the United States , and establishes Folium as Nutralliance’s exclusive CBD supplier.
Headquartered in Colorado Springs, Colo. , Folium Biosciences is a vertically integrated B2B producer, manufacturer, and distributor of hemp-derived non-psychoactive cannabinoids. Built on the core tenets of quality, science, scale, and innovation, Folium Biosciences controls all aspects of the supply chain from genetics and extraction to bulk and finished products. Folium Biosciences’ team of scientists, chemists, engineers, and other committed professionals delivers the world’s highest-quality hemp-derived non-psychoactive cannabinoids products through a proprietary process, resulting in a THC content of 0.0%. Folium Biosciences was the first hemp company to be issued a Certificate of Free Sale and a Manufactured Food Establishment License by the Colorado Department of Public Health and Environment and continues to lead the industry in regulatory compliance and governance.
Folium submitted the application in response to the 2020 FSA requirement that all CBD products on the UK market have a novel food application through the validation phase of the review process before March 31, 2021. CBD food products that fail to gain regulatory approval before the deadline will no longer be allowed to sell their goods in the UK. The Folium application is unique because it is based on a botanical extract instead of a purified CBD material used in other applications. This submission follows Folium’s core belief that the CBD industry should align its products and practices with what nature provides.
Folium’s application also included white-label finished products from the company and its UK customers’ finished products – along with the company’s Broad Spectrum Hemp Oil Water Soluble Powder. Novel foods approval will therefore ensure that Folium’s customer partners are able to maintain their market advantage with both white-label and custom formulations. “Following the FSA guidelines is in line with our ‘not all hemp is created equal’ promise in many ways, but perhaps most importantly because it communicates unequivocally that we’re very intentional when it comes to delivering the best for our customers,” added Fernandez. “This novel food application is one more essential step in ensuring continued compliance for our customers, as well as our products, in the European market.”
Colorado Springs, Colo. – Folium Biosciences has submitted a novel food application to the UK Food Standards Agency (FSA) for validation of its hemp-derived, 0.0% THC broad-spectrum CBD (cannabidiol) oil. The application was submitted on behalf of Folium Biosciences Europe B.V. and a consortium of the company’s diverse, UK-based CBD product customer partners.
“Folium has a long-standing track record for quality, safety, consistency and supply chain transparency that has enabled us to secure approvals from ethical commissions and regulatory bodies around the world – even in countries with stringent cannabinoid regulations, such as Japan, Australia, New Zealand and South America,” said Folium Chief Scientific Officer Vanesa Fernandez. “We’re proud to be continuing to demonstrate global CBD leadership as an active participant in the UK’s regulatory advances, and look forward to moving through the novel foods regulatory process next in the EU. It’s in the best interest of everyone in the CBD industry and the end customers we serve to make product quality and compliance our top priority.”